Assessing patient-centered outcomes in rare diseases is essential for understanding treatment benefit. However, patient heterogeneity introduces an extra layer of complexity in assessing outcomes. We have expertise in identifying concepts and developing endpoint strategies for rare heterogenous diseases, leveraging expertise from COA consulting, clinical development, and health economics and outcomes research.